| Filed On | Filing |
|---|---|
| 06 Oct 2026 |
Form 4: Greenleaf Peter, Director
Sold 797 shares ($16.9K) |
| 06 Oct 2026 |
Form 4: Friedberg Ezra M, Director
Sold 558 shares ($11.6K) |
| 06 Oct 2026 |
Form 4: Pauls Matthew, Director
Sold 786 shares ($16.5K) |
| 01 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders
(a) The purpose of this 2026 Equity Incentive Plan (the “Plan”) is to encourage key service providers of Pelthos Therapeutics Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by ... |
| 18 Aug 2026 | ARS |
| 18 Aug 2026 | DEFA14A |
| 18 Aug 2026 | Proxy statement: annual meeting on September 29, 2026 |
| 13 Aug 2026 | 10-Q/A |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 13 Aug 2026 | 8-K: Non-Reliance on Previously Issued Financial Statements |
| 07 Aug 2026 | PRE 14A |
| 07 Jul 2026 |
Form 4: Friedberg Ezra M, Director
Sold 558 shares ($14.6K) |
| 07 Jul 2026 |
Form 4: Pauls Matthew, Director
Sold 786 shares ($20.6K) |
| 07 Jul 2026 |
Form 4: Greenleaf Peter, Director
Sold 797 shares ($20.8K) |
| 17 Jun 2026 |
Form 4: Friedberg Ezra M, Director
Sold 283 shares ($7.72K) |
| 15 Jun 2026 |
Form 4: Davis Todd C, Director
Bought 35,948 shares ($1M) |
| 28 May 2026 | 8-K: Regulation FD Disclosure |
| 26 May 2026 |
Form 4: Francis Knuettel Ii, CFO, Treas & Secty
Returned 13,947 shares to the issuer · Sold 1,500 shares ($40.3K) · Granted 59,500 Stock Option · 1 more |
| 22 May 2026 | 144 |
Loading...
